Instil Bio Discontinues ITIL-168 Cancer Trials, Layoffs 60% Of Its Employees

  • Instil Bio Inc TIL announced a reprioritization of its clinical programs to focus on developing its CoStAR-TIL product candidates.
  • The company has prioritized the development of its proprietary, genetically-engineered CoStAR-TIL programs, designed to boost the efficacy of T cells within the tumor microenvironment (TME). 
  • Instil's lead CoStAR-TIL program, ITIL-306 is in a Phase 1 dose escalation trial in non-small cell lung cancer (NSCLC), ovarian cancer, and renal cell carcinoma. 
  • The company expects to report data from the dose escalation cohorts of Phase 1 ITIL-306 study in 2023.
  • In October, the company voluntarily paused enrollment in its ongoing ITIL-306 trial as part of its overall manufacturing analysis.
  • Instil is undertaking a reduction in its U.S. workforce of approximately 60% to realign its operating model from a registration-focused company to a development-stage company.
  • Instil is discontinuing its ITIL-168 clinical programs, the DELTA-1 trial in advanced melanoma and the DELTA-2 trial in NSCLC, cervical cancer, and head and neck squamous cell carcinoma.
  • Price Action: TIL shares are down 17.20% at $1.01 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!